Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07310901 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Study acronym: CANYON-1
StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 5 entries Trial completed · Primary completion date changed from estimate of Jul 2, 2026 to Aug 3, 2026 · Enrollment target: estimated 252 to confirmed 254 · 1 more Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jul 2, 2026 to Aug 3, 2026
    • Enrollment target: estimated 252 to confirmed 254
    • Eligibility criteria expanded, about 22 words
  2. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 15 of 15 sitesv5 Show 1 more changeShow less
    • Site details revised at 15 of 15 sites
  3. Site details revised at 2 of 15 sitesv4
  4. Site details revised at 11 of 15 sitesv3
  5. Site details revised at 15 of 15 sitesv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.
Trial Details
NCT Number NCT07310901
Lead Sponsor Corbus Pharmaceuticals Inc.
Conditions Obese But Otherwise Healthy Participants
Enrollment 254 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov